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Abstract
Low density lipoprotein receptor-related protein 1 (LRP1) is a ubiquitously expressed cell surface receptor that
mediates the internalization of more than 40 different ligands and participates in cell signaling. LRP1 plays
a key pathophysiological role in the onset, development and thrombotic resolution of the atherosclerotic
process due to its role in the intracellular lipid accumulation of vascular smooth muscle cells (VSMCs).
During last years, LRP1 has also been proposed as a modulator of the inflammatory phenomenon in
atherosclerosis. However, the investigations have obviated the function of LRP1 as a binding receptor
of modified-lipids. In addition, the studies that analysed the relation between inflammation and LRP1
are focused on immunological cells from mice models. Whether LRP1 can respond to its modified-LDL
ligands developing an inflammatory response in human VSMCs is unknown. Further investigations are, thus,
necessary.
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Low-density lipoprotein receptor-related protein-1
(LRP1) is an ubiquitously expressed and
multifunctional membrane receptor involved in
diverse biological processes, including lipoprotein
metabolism, modulation of vascular and blood
brain barrier integrity, activation of lysosomal
enzymes and cell migration, among others [1].
LRP1 mediates the internalization of more than
40 different ligands and participates in intracellular
signalling [1,2]. Alterations in receptor expression
are associated with several pathological conditions
such as Alzheimer's disease, cardiovascular disease or
cancer [3,4].
Deregulation of vascular LRP1 expression is a
key event in the etiology of atherosclerosis. LRP1
receptor is involved in the binding and internalization
of matrix-retained aggregated LDL (agLDL), a major
modification of LDL in the arterial intima, which leads
to the intracellular lipid accumulation in vascular
smooth muscle cells (VSMCs) [5,6]. This mechanism
is fundamental for VSMCs to become foam cells, an
essential step in the initiation and progression of
atherosclerosis [7]. Additionally to its role in foam cell
formation, LRP1 plays a central pathophysiological
role in vascular remodeling [8] and prothrombotic
transformation of the atheromatous plaque [9].
Indeed, agLDL uptake by LRP1 affects the expression
and activation of tissue factor, principal activator
of coagulation, and the secretion of microparticles
enriched in tissue factor, situations associated with
acute coronary syndrome and metabolic syndrome
[9]. LRP1-mediated VSMCs-lipid loading contributes
to the alterations in the elastogenic/elastolytic
potential of human vascular cells reducing the
tropoelastin synthesis and altering the structure and
dynamics of elastin [10]. Moreover, the accumulation
of cholesterol esters mediated by LRP1 increases
the expression of precursor and mature forms
of the proteolytic enzyme cathepsin S, linked to
extracellular matrix degradation [10].
During last decade LRP1 has long been
proposed as a modulator of the inflammatory
phenomenon in atherosclerosis. Using a transgenic
mice that specifically lacks macrophage LRP1,
Overton and colleagues demonstrated that LRP1
deletion initiates a pro-inflammatory response
through increased secretion of pro-inflammatory
and pro-atherogenic mediators, such as TNF-
α and MCP-1 [11]. They also found that
macrophage LRP1 deletion increases MMP-9
expression and activity indicating that LRP1
is essential for vascular integrity. Additionally,
inhibition of mice macrophage LRP1 impairs cell
migration [12], down-regulates anti-inflammatory
marker expression and enhances the response to
classic inflammatory activation stimuli [13]. LRP1
affects inflammatory signaling directly, through the
binding of extracellular messengers or intracellular
signaling molecules, or indirectly through interaction
of LRP1 with other transmembrane receptors or
endocytosis of extracellular factors [14]. Zurhove
and colleagues proposed that LRP1 limits the
LPS-induced inflammatory response by interacting
with the interferon regulatory transcription factor
3 (IRF-3) and inducing its nuclear export and
proteosomal degradation in murine peritoneal
2macrophages [15]. Macrophage LRP1 deficiency
increases cell death and inflammation by impairing
phosphorylated Akt activation [16]. Finally, Gaultier
and colleagues reported that expression of
complement components is increased in LRP1-
deficient macrophages, isolated from mice [17].
They proposed that LRP1 supresses basal activity of
nuclear factor kB (NF-kB) pathway by regulating TNF
receptor 1 (TNFR1) cell surface level.
Attending to this previous evidence, LRP1 is
a key inflammatory regulator in atherosclerosis.
Nevertheless, additional approaches to better
understand the relationship between LRP1,
inflammation and atherosclerosis are necessary. It
has been clearly demonstrated that the interaction
between lipids and inflammation plays a relevant
role in the atherosclerotic process [18-20]. Modified
lipids act on diverse cell types to instigate
inflammation and proatherogenic mechanisms [21].
Due to its properties in modified-LDL interaction
and inflammatory signaling, LRP1 is the perfect
candidate for the crosstalk between lipid metabolism
and inflammation. However, the investigations
have obviated the pathophysiological function of
LRP1 as a binding receptor of modified-lipids. In
addition, the studies that analysed the relation
between inflammation and LRP1 are focused on
immunological cells of animal models. Recently,
our group has demonstrated that agLDL per se
increased LRP1 expression in human monocyte-
derived macrophages (HMDM)   [22]. Furthermore,
we have reported a direct association between
LRP1 levels and inflammatory mediators secretion in
human VSMCs in hypoxic conditions [23]. However,
whether LRP1 can respond to its modified-LDL
ligand by inflammatory signaling or alterations in
the release of inflammatory factors in VSMCs is
unknown. Since VSMCs are crucial for foam cell
generation and its inflammatory function in human
atheroma plaque has long been underestimated,
further investigations are fundamental [24]. The
presumed effect of agLDL-LRP1 interaction on the
regulation of inflammatory mechanisms could bring
knowledge for understanding the molecular basis
of atherosclerosis and opens the door to possible
therapies.
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